Last reviewed · How we verify
Serine Proteinase Inhibitor WX-671 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Serine Proteinase Inhibitor WX-671 (Serine Proteinase Inhibitor WX-671) — Heidelberg Pharma AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Serine Proteinase Inhibitor WX-671 TARGET | Serine Proteinase Inhibitor WX-671 | Heidelberg Pharma AG | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Serine Proteinase Inhibitor WX-671 CI watch — RSS
- Serine Proteinase Inhibitor WX-671 CI watch — Atom
- Serine Proteinase Inhibitor WX-671 CI watch — JSON
- Serine Proteinase Inhibitor WX-671 alone — RSS
Cite this brief
Drug Landscape (2026). Serine Proteinase Inhibitor WX-671 — Competitive Intelligence Brief. https://druglandscape.com/ci/serine-proteinase-inhibitor-wx-671. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab